Monday, October 29, 2007
Dr. Tjark Reblin
Paul Lucas, President and CEO of GlaxoSmithKline Inc., is pleased to announce the following appointment:
Dr. Tjark Reblin becomes GSK Inc.’s Vice-President, Medical and Chief Medical Officer, leading the company’s Canadian medical division.
Dr. Reblin joined GSK in 2000 as a Director in the Therapy Area of Internal Medicine. Most recently, Dr. Reblin held the role of Medical Director in the company’s Metabolic Centre of Excellence in Europe, where he provided critical support and leadership in developing European medical strategies for all products in the metabolic therapy area.
Dr. Reblin received his MD from the University of Hamburg and an MBA from the Fuqua School of Business at Duke University and Goethe Business School at Frankfurt University.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and health-care companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. In Canada, GlaxoSmithKline is among the top 15 investors in research and development, contributing more than $176 million in 2006 alone. GSK is an Imagine Caring Company, and is consistently recognized as one of the 50 Best Employers in Canada.
Back to top